Surgical genomics is here

Surgery

Volumn 133, Issue 2, 2003, Pages 127-132

  Johnson, Jeffrey L ^a   Harken, Alan H ^a  

^a DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

BIOINFORMATICS; DNA POLYMORPHISM; EQUIPMENT; ETHICS; GENE FUNCTION; GENETIC ANALYSIS; GENETIC CODE; GENETIC VARIABILITY; GENOMICS; HUMAN; HUMAN GENOME; MEDICAL PRACTICE; MOLECULAR GENETICS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SURGICAL STRESS; SURGICAL TECHNIQUE;

EID: 0037306445     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1067/msy.2003.75     Document Type: Review

References (18)

1. Shames BD, Selzman CH, Meng X, et al. Genes don't count. Arch Surg 1998; 133:667-9.
2. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995; 86:1243-54.
3. Biffl WL, Moore EE, Moore FA. Interleukin-6 In The Injured Patient. Marker Of Injury Or Mediator Of Inflammation? Ann Surg 1996; 224:647-64.
4. Syvanen AC. Accessing genetic variation: genotyping single nucleotide polymorphisms. Nat Rev Genet 2001; 2:930-42.
5. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000; 275:18138-44.
6. Brull DJ, Montgomery HE, Sanders J, et al. Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 2001; 21:1458-63.
7. Menges T, Hermans PW, Little SG, et al. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet 2001; 357:1096-7.
8. Jones KG, Brull DJ, Brown LC, et al. Interleukin-6 and the Prognosis of Abdominal Aortic Aneurysms. Circulation 2001; 103:2260-5.
9. Shi MM. Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies. Clin Chem 2001; 47:164-72.
10. Devlin B, Roeder K, Bacanu SA. Unbiased methods for population-based association studies. Genet Epidemiol 2001; 21:273-84.
11. Fernandez Zapico ME, Ahmad US, Urrutia R. DNA microarrays: Revolutionary insight into the living genome. Surgery 2001; 130:403-7.
12. Yeung KY, Ruzzo WL. Principal component analysis for clustering gene expression data. Bioinformatics 2001; 17:763-74.
13. Yang YH, Speed T. Design issues for cDNA microarray experiments. Nat Rev Genetics 2002; 3:579-88.
14. Mills APJ. Gene expression profiling diagnosis through DNA molecular computation. Trends Biotechnol 2002; 20:137-40.
15. Brazma A, Hingamp P, Quackenbush J, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001; 29:365-71.
16. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. Jama 2001; 286:2270-9.
17. Annas GJ. The limits of state laws to protect genetic information. N Engl J Med 2001; 345:385-8.
18. Greely HT. Human genomics research. New challenges for research ethics. Perspect Biol Med 2001; 44:221-9.